Schizophrenia Research
Volume 96, Issue 1 , Pages 169-184 , November 2007

The neuropsychological correlates of cannabis use in schizophrenia: Lifetime abuse/dependence, frequency of use, and recency of use

  • Carissa M. Coulston

      Affiliations

    • Academic Discipline of Psychological Medicine, Northern Clinical School, University of Sydney, New South Wales, Australia
    • CADE Clinic, Department of Academic Psychiatry, Royal North Shore Hospital, St. Leonards, Sydney, New South Wales, Australia
    • Corresponding Author InformationCorresponding author. CADE Clinic, Department of Academic Psychiatry, Level 5, Building 36, Royal North Shore Hospital, St. Leonards, NSW, 2065, Australia. Tel.: +61 2 9926 7746; fax: +61 2 9926 7730.
    • ,
  • Michael Perdices

      Affiliations

    • Academic Discipline of Psychological Medicine, Northern Clinical School, University of Sydney, New South Wales, Australia
    • Department of Neurology, Royal North Shore Hospital, St. Leonards, Sydney, New South Wales, Australia
    • ,
  • Christopher C. Tennant

      Affiliations

    • Academic Discipline of Psychological Medicine, Northern Clinical School, University of Sydney, New South Wales, Australia

Received 13 April 2007 ,Revised 6 August 2007 ,Accepted 7 August 2007.

References 

  1. Acquas E, Pisanu A, Marrocu P, Goldberg SR, Di Chiara G. Δ9-Tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study. Eur. J. Pharmacol. 2001;419:155–161
  2. Addington D, Addington J, Maticka-Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr. Res. 1992;6:201–208
  3. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br. J. Psychiatry. 1993;163(Suppl 22):39–44
  4. Addington D, Addington J, Atkinson M. A psychometric comparison of the Calgary Depression Scale for schizophrenia and the Hamilton Depression Rating Scale. Schizophr. Res. 1996;19:205–212
  5. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington, D.C: APA; 1994;
  6. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa; 1983;
  7. Andreasen NC. The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa; 1984;
  8. Barry KL, Fleming MF, Greenley J, Widlak P, Kropp S, McKee D. Assessment of alcohol and other drug disorders in the seriously mentally ill. Schizophr. Bull. 1995;21:313–321
  9. Benes FM, Vincent SL, Marie A, Kahn Y. Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience. 1996;75:1021–1031
  10. Clarke HF, Dalley JW, Crofts HS, Robbins TW, Roberts AC. Cognitive inflexibility after prefrontal serotonin depletion. Science. 2004;304:878–880
  11. Collie A, Darby D, Maruff P. Computerised cognitive assessment of athletes with sports related head injury. Br. J. Sports Med. 2001;35:297–302
  12. Comrey AL, Lee HB. A First Course in Factor Analysis. Second Edition. Hillsdale, NJ: Lawrence Erlbaum Associates; 1992;
  13. Coulston, C.M, Perdices, M., Tennant, C.C., in press. The neuropsychology of cannabis and other substance use in schizophrenia: review of the literature and critical evaluation of methodological issues. Aust. N. Z. J. Psychiatry.
  14. Coyle JT. The GABA-glutamate connection in schizophrenia: which is the proximate cause?. Biochem. Pharmacol. 2004;68:1507–1514
  15. Dalley JW, Theobald DE, Pereira EAC, Li PMMC, Robbins TW. Specific abnormalities in serotonin release in the prefrontal cortex of isolation-reared rats measured during behavioural performance of a task assessing visuospatial attention and impulsivity. Psychopharmacology. 2002;164:329–340
  16. Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend. 2003;71:37–48
  17. Delis DC, Kaplan E, Kramer JH. The Delis–Kaplan Executive Function System (D-KEFS). The Psychological Corporation: A Harcourt Assessment Company; 2001;
  18. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu Y, et al. The psychotomimetic effects of Delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29:1558–1572
  19. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, et al. Δ9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiatry. 2005;57:594–608
  20. Ferraro L, Tomasini MC, Gessa GL, Bebe BW, Tanganelli S, Antonelli T. The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study. Cereb. Cortex. 2001;11:728–733
  21. First MB, Gibbon M, Spitzer RL, Williams JBW. User's Guide for the SCID-I Structured Clinical Interview for DSM-IV-TR Axis I Disorders (Research Version). Biometrics Research. 2001;
  22. Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol. Psychiatry. 1999;45:1–16
  23. Gollin ES. Developmental studies of visual recognition of incomplete objects. Percept. Mot. Skills. 1960;11:289–298
  24. Hall W. Cannabis use and psychosis. Drug Alcohol Rev. 1998;17:433–444
  25. Hall W. Reducing the harms caused by cannabis use: the policy debate in Australia. Drug Alcohol Depend. 2001;62:163–174
  26. Hemsley DR. Attention and information processing in schizophrenia. Br. J. Soc. Clin. Psychol. 1976;15:199–209
  27. Hemsley DR. Perception and cognition in schizophrenia. In:  Cromwell RL,  Snyder CR editor. Schizophrenia: Origins, Processes, Treatment, and Outcome. London: Oxford University Press; 1993;p. 135–150
  28. Hemsley DR. A simple (or simplistic?) cognitive model for schizophrenia. Behav. Res. Ther. 1993;31:633–645
  29. Hooper HE. The Hooper Visual Organization Test (Manual). Beverly Hills, CA: Western Psychological Services; 1958;
  30. Hooper HE. Hooper Visual Organisation Test (VOT). Los Angeles: Western Psychological Services; 1983;
  31. Huestis MA, Cone EJ. Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J. Anal. Toxicol. 1998;22:445–454
  32. Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without effect in the nucleus accumbens or striatum. Neuropsychopharmacology. 2002;26:325–339
  33. Jentsch JD, Andrusiak E, Tran A, Bowers MB, Roth RH. Δ9-Tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966. Neuropsychopharmacology. 1996;16:426–432
  34. Jentsch JD, Verrico CD, Le D, Roth RH. Repeated exposure to Δ9-tetrahydrocannabinol reduces prefrontal cortical dopamine metabolism in the rat. Neurosci. Lett. 1998;246:169–172
  35. Jockers-Scherübl MC, Wolf T, Radzei N, Schlattmann P, Rentzsch J, Gómez-Carrillo de Castro A, et al. Cannabis induces different cognitive changes in schizophrenic patients and healthy controls. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2007;31:1054–1063
  36. Kongs SK, Thompson LL, Iverson GL, Heaton RK. Wisconsin Card Sorting Test-64 Card Version: Professional Manual. Odessa, Florida: Psychological Assessment Resources; 2000;
  37. Kumra S, Thaden E, DeThomas C, Kranzler H. Correlates of substance abuse in adolescents with treatment-refractory schizophrenia and Schizoaffective disorder. Schizophr. Res. 2005;73:369–371
  38. Liraud F, Verdoux H. Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders. Encephale. 2002;28:160–168(French)
  39. Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav. Res. Ther. 1995;33:335–343
  40. Mueser KT, McGurk SR. Schizophrenia. Lancet. 2004;363:2063–2072
  41. Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Mol. Brain Res. 1998;56:207–217
  42. Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC. Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia: focus on GABA content, GABAA receptor α-1 subunit messenger RNA and human GABA transporter-1 (HGAT-1) messenger RNA expression. Neuroscience. 1999;93:441–448
  43. Pantelis C, Maruff P. The cognitive neuropsychiatric approach to investigating the neurobiology of schizophrenia and other disorders. J. Psychosom. Res. 2002;53:655–664
  44. Pencer A, Addington J. Substance use and cognition in early psychosis. J. Psychiatry Neurosci. 2003;28:48–54
  45. Peters ER, Nunn JA, Pickering AD, Hemsley DR. Perceptual organization deficits in psychotic patients. Psychiatry Res. 2002;110:125–135
  46. Pistis M, Ferraro L, Pira L, Flore G, Tanganelli S, Gessa GL, et al. Δ9-Tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res. 2002;948:155–158
  47. Pope HG, Gruber AJ, Hudson JI, Huestis M, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch. Gen. Psychiatry. 2001;58:909–915
  48. Rey A. L'Examen Clinique en Psychologie. Paris: Presses Universitaires de France; 1964;
  49. Rhee M-H, Nevo I, Avidor-Reiss T, Levy R, Vogel Z. Differential superactivation of adenylyl cyclase isozymes after chronic activation of the CB1 cananbinoid receptor. Mol. Pharmacol. 2000;57:746–752
  50. Ruff RM, Allen CC. Ruff 2 and 7 Selective Attention Test: Professional Manual. PAR: Psychological Assessment Resources, Inc; 1996;
  51. Sarter M, Bruno JP. Abnormal regulation of corticopetal cholinergic neurons and impaired information processing in neuropsychiatric disorders. Trends Neurosci. 1999;22:67–74
  52. Seaton BE, Goldstein G, Allen DN. Sources of heterogeneity in schizophrenia: the role of neuropsychological functioning. Neuropsychol. Rev. 2001;11:45–66
  53. Serper MR, Bergman A, Copersino ML, Chou JCY, Richarme D, Cancro R. Learning and memory impairment in cocaine-dependent and comorbid schizophrenic patients. Psychiatry Res. 2000;93:21–32
  54. Serper MR, Copersino ML, Richarme D, Vadhan N, Cancro R. Neurocognitive functioning in recently abstinent, cocaine-abusing schizophrenic patients. J. Subst. Abuse. 2000;11:205–213
  55. Sevy S, Burdick KE, Visweswaraiah H, Abdelmessih S, Lukin M, Yechiam E, et al. Iowa Gambling Task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders. Schizophr. Res. 2007;92:74–84
  56. Shipley WC. A self-administering scale for measuring intellectual impairment and deterioration. J. Psychol. 1940;9:371–377
  57. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. J. Am. Med. Assoc. 2002;287:1123–1131
  58. Sim-Selley LJ. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit. Rev. Neurobiol. 2003;15:91–119
  59. Spreen O, Strauss E. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. Second Edition. Oxford: Oxford University Press; 1998;
  60. Stirling J, Lewis S, Hopkins R, White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr. Res. 2005;75:135–137
  61. Stirling J, White C, Lewis S, Hopkins R, Tantam D, Huddy A, et al. Neurocognitive function and outcome in first-episode schizophrenia: a 10-year follow-up of an epidemiological cohort. Schizophr. Res. 2003;65:75–86
  62. Taylor EM. Psychological Appraisal of Children with Cerebral Deficits. Cambridge, MA: Harvard University Press; 1959;
  63. Verrico CD, Jentsch JD, Dazzi L, Roth RH. Systemic, but not local, administration of cannabinoid CB1 receptor agonists modulate prefrontal cortical acetylcholine efflux in the rat. Synapse. 2003;48:178–183
  64. Warrington EK, James M. Visual Object and Space Perception Battery. Suffolk, England: Thames Valley Test Co.; 1991;
  65. Weinberger R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry. 1987;44:660–669
  66. Zachary RA. Shipley Institute of Living Scale — Revised Manual. Los Angeles: Western Psychological Services; 1994;
  67. Zavitsanou K, Ward PB, Huang X-F. Selective alterations in ionotropic glutamate receptors in the anterior cingulate cortex in schizophrenia. Neuropsychopharmacology. 2002;27:826–833

PII: S0920-9964(07)00362-3

doi: 10.1016/j.schres.2007.08.006

Schizophrenia Research
Volume 96, Issue 1 , Pages 169-184 , November 2007

Article Tools